Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deoxycytidine/deoxythymidine - Modis Therapeutics

Next Previous
Drug Profile

Deoxycytidine/deoxythymidine - Modis Therapeutics

Alternative Names: dC/dT - Modis Therapeutics; Deoxycytidine/deoxythymidine; Doxecitine/Doxribtimine - UCB; doxTM; KYGEVVI; MT 1621 - UCB; MT-1621; Thymidine/deoxycytidine - Modis Therapeutics

Latest Information Update: 05 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Columbia University Medical Center; Vall d-Hebron Research Institute
  • Developer Modis Therapeutics
  • Class Alcohols; Amines; Cyclic ethers; Deoxyribonucleosides; Furans; Pyrimidinones; Small molecules
  • Mechanism of Action Deoxyribonucleoside replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mitochondrial disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Mitochondrial disorders

Most Recent Events

  • 30 Jan 2026 Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommends approval of Deoxycytidine/deoxythymidine forMitochondrial disorders (In adolescents, In adults, In children, In the elderly) in European Union
  • 05 Nov 2025 Columbia University Irving Medical Center and Vall d'Hebron Research Institute have patent protection for Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes in USA, Spain, Australia, Europe and Japan
  • 05 Nov 2025 Columbia University Irving Medical Center and Vall d'Hebron Research Institute have patents pending for Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes in South Korea, Canada, Israel, China, Poland, Lithuania, Mexico, Denmark, Portugal, Hungary, Russia, San Marino, Brazil and Croatia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top